Values as of: 2024-12-24
COMMON STOCK | Medical Devices |
Last Closing
USD 13.02Change
-1.16 (-8.18)%Market Cap
USD 4.17BVolume
252.00Analyst Target
N/AVerdict
Verdict
Ambu A/S, a medical technology company, develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, gastroscopes, cystoscopes, and displaying units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products; airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers extrication collars, resuscitators, video laryngoscopes, and training manikins. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.
Company Website : https://www.ambu.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SEMHF | Siemens Healthineers AG |
N/A |
USD 62.73B |
| SMMNY | Siemens Healthineers AG ADR |
+0.04 (+0.15%) |
USD 60.88B |
| RYLPF | Koninklijke Philips N.V |
N/A |
USD 24.07B |
| SONVF | Sonova Holding AG |
N/A |
USD 19.64B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 11.03B |
| WILLF | Demant A/S |
N/A |
USD 8.53B |
| GNGBF | Getinge AB |
N/A |
USD 4.32B |
| GNNDY | GN Store Nord A/S ADR |
-0.78 (-1.41%) |
USD 2.85B |
| GGNDF | GN Store Nord A/S |
N/A |
USD 2.83B |
| NHNKY | Nihon Kohden Corp ADR |
-0.07 (-0.49%) |
USD 2.31B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -14.90% | 58% | F | 44% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -14.90% | 58% | F | 42% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -13.92% | 61% | D- | 45% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -13.92% | 61% | D- | 42% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -22.01% | 62% | D | 54% | F | ||
| Dividend Return | 0.55% | 5% | F | 1% | F | ||
| Total Return | -21.46% | 63% | D | 48% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 5.40% | 50% | F | 46% | F | ||
| Dividend Return | 5.47% | 50% | F | 42% | F | ||
| Total Return | 0.07% | 18% | F | 7% | C- | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 55.52% | 59% | D- | 48% | F | ||
| Risk Adjusted Return | 9.85% | 52% | F | 42% | F | ||
| Market Capitalization | 4.17B | 93% | A | 84% | B | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
